Abstract
Cancer is one of the main causes of death among humans, second only to cardiovascular diseases. In recent years, numerous studies have been conducted on the pathophysiology of cancer, and it has been established that this disease is developed by a group of stem cells known as cancer stem cells (CSCs). Thus, cancer is considered a stem cell disease; however, there is no comprehensive consensus about the characteristics of these cells. Several different signaling pathways including Notch, Hedgehog, transforming growth factor-β (TGF-β), and WNT/β-catenin pathways cause the self-renewal of CSCs. CSCs change their metabolic pathways in order to access easy energy. Therefore, one of the key objectives of researchers in cancer treatment is to destroy CSCs. Nuclear factor erythroid 2-related factor 2 (Nrf2) plays an essential role in the protection of CSCs from reactive oxygen species (ROS) and chemotherapeutic agents by regulating antioxidants and detoxification enzymes. Human epidermal growth factor receptor 2 (HER2) is a member of the tyrosine kinase receptor family, which contributes to the protection of cancer cells against treatment and implicated in the invasion, epithelial-mesenchymal transition (EMT), and tumorigenesis. Aldehyde dehydrogenases (ALDHs) are highly active in CSCs and protect the cells against damage caused by active aldehydes through the regulation of aldehyde metabolism. On the other hand, ALDHs promote the formation and maintenance of tumor cells and lead to drug resistance in tumors through the activation of various signaling pathways, such as the ALDH1A1/HIF-1α/VEGF axis and Wnt/β-catenin, as well as changing the intracellular pH value. Given the growing body of information in this field, in the present narrative review, we attempted to shed light on the function of Nrf2, HER2, and ALDH in CSCs.
Graphical abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
No datasets were generated or analysed during the current study.
References
Abgarmi ZM, Lotfi AS, Abroun S, Soleimani M, Ganji SM (2018) Inhibition of Erbb2 by trastuzumab induces oxidative stress markers in HER2 positive breast cancer cell lines. J Res Med Dental Sci 6(3):158–165
Ayob AZ, Ramasamy TS (2018) Cancer stem cells as key drivers of tumour progression. J Biomed Sci 25(1):20. https://doi.org/10.1186/s12929-018-0426-4
Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23(10):1124
Bayik D, Lathia JD (2021) Cancer stem cell–immune cell crosstalk in tumour progression. Nat Rev Cancer 21(8):526–536
Bomken S, Fišer K, Heidenreich O, Vormoor J (2010) Understanding the cancer stem cell. Br J Cancer 103(4):439–445
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3(2):224–237
Burdick AD, Davis JW 2nd, Liu KJ, Hudson LG, Shi H, Monske ML, Burchiel SW (2003) Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Can Res 63(22):7825–7833
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676–3685
Cahan P, Daley GQ (2013) Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol 14(6):357–368
Chakraborty S, Balan M, Flynn E, Zurakowski D, Choueiri TK, Pal S (2019) Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis 8(2):7. https://doi.org/10.1038/s41389-018-0116-9
Chan AW, Tong JH, Chan SL, Lai PB, To KF (2014) Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 64(7):935–950. https://doi.org/10.1111/his.12342
Chen J (2014) Reactive oxygen species and drug resistance in cancer chemotherapy. Austin J Clin Pathol 1(4):1–7
Chen S, Zhao Y, Shen F, Long D, Yu T, Lin X (2019) Introduction of exogenous wild-type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor-κB in non-small cell lung cancer NCI-H1299 cells. Oncol Rep 41(3):2051–2059
Chhikara BS, Parang K (2023) Global cancer statistics 2022: the trends projection analysis. Chem Biol Lett 10(1):451–451
Choi B-H, Kim JM, Kwak M-K (2021) The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. Arch Pharmacal Res 44(3):263–280
Clark DW, Palle K (2016) Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med 4(24):518–518. https://doi.org/10.21037/atm.2016.11.82
Copple IM, Goldring CE, Kitteringham NR, Park BK (2008) The Nrf2–Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 246(1):24–33
De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B et al (2011) High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica 96(10):1548–1551. https://doi.org/10.3324/haematol.2011.043786
Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA et al (2020) Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol 235(4):3142–3156
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al (2009a) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780. https://doi.org/10.1038/nature07733
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al (2009b) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783. https://doi.org/10.1038/nature07733
Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH (2002) Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via epidermal growth factor receptor. FASEB J 16(13):1–21
Dogan I, Cumaoglu A, Aricioglu A, Ekmekci A (2011) Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem 347:41–51
Durko L, Wlodarski W, Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M, Hogendorf P et al (2017) Expression and clinical significance of cancer stem cell markers CD24, CD44, and CD133 in pancreatic ductal adenocarcinoma and chronic pancreatitis. Dis Markers. https://doi.org/10.1155/2017/3276806
Fattahi M, Sheervalilou R, Hoseinpour N, Valiloo M, Pedram N, Montazeri V et al (2020) The correlation between twist 1 and 2 promoter methylation status and clinicopathologic characteristics of patients with breast cancer. Gene Rep 20:100741
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013–e180013
Fulawka L, Donizy P, Halon A (2014) Cancer stem cells–the current status of an old concept: literature review and clinical approaches. Biol Res 47(1):66
Gianni D, Taulet N, DerMardirossian C, Bokoch GM (2010) c-Src–mediated phosphorylation of NoxA1 and Tks4 induces the reactive oxygen species (ROS)–dependent formation of functional invadopodia in human colon cancer cells. Mol Biol Cell 21(23):4287–4298
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567
Halliwell B (2007) Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death. Free radicals in biology and medicine, 187–267.
Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N et al (2009) Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15(10):3423–3432. https://doi.org/10.1158/1078-0432.ccr-08-2822
Islam SS, Uddin M, Noman ASM, Akter H, Dity NJ, Basiruzzman M et al (2019) Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1. EBioMedicine 43:211–224
Jung B-J, Yoo H-S, Shin S, Park Y-J, Jeon S-M (2018) Dysregulation of NRF2 in cancer: from molecular mechanisms to therapeutic opportunities. Biomol Ther 26(1):57
Kahroba H, Shirmohamadi M, Hejazi MS, Samadi N (2019) The Role of Nrf2 signaling in cancer stem cells: from stemness and self-renewal to tumorigenesis and chemoresistance. Life Sci 239:116986
Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z (2017) Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res 23(4):793–802. https://doi.org/10.1007/s12253-016-0169-z
Kapucuoğlu N, Bozkurt KK, Başpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, Akçil M (2015) The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol-Res Pract 211(10):740–747
Kensler TW, Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31(1):90–99. https://doi.org/10.1093/carcin/bgp231
Khodabandeh Z, Valilo M, Velaei K, Pirpour Tazehkand A (2022) The potential role of nicotine in breast cancer initiation, development, angiogenesis, invasion, metastasis, and resistance to therapy. Breast Cancer 29(5):778–789
Kim KH, Kang YJ, Jo JO, Ock MS, Moon SH, Suh DS et al (2014) DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers. Biochem Biophys Res Commun 447(2):315–322. https://doi.org/10.1016/j.bbrc.2014.03.144
Kim R, Kim SB, Cho EH, Park SH, Park SB, Hong SK, Chae G (2015) CD44 expression in patients with combined hepatocellular cholangiocarcinoma. Ann Surg Treat Res 89(1):9–16. https://doi.org/10.4174/astr.2015.89.1.9
Klemba A, Purzycka-Olewiecka JK, Wcisło G, Czarnecka AM, Lewicki S, Lesyng B et al (2018) Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. Contemp Oncol (poznan, Poland) 22(1A):48–55. https://doi.org/10.5114/wo.2018.73885
Korkaya H, Wicha MS (2013) HER2 and breast cancer stem cells: more than meets the eye. Can Res 73(12):3489–3493
Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27(47):6120–6130. https://doi.org/10.1038/onc.2008.207
Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE (2009) Mitochondria and reactive oxygen species. Free Radical Biol Med 47(4):333–343. https://doi.org/10.1016/j.freeradbiomed.2009.05.004
Kuznetsov AV, Kehrer I, Kozlov AV, Haller M, Redl H, Hermann M et al (2011) Mitochondrial ROS production under cellular stress: comparison of different detection methods. Anal Bioanal Chem 400(8):2383–2390. https://doi.org/10.1007/s00216-011-4764-2
Kwak M-K, Cho J-M, Huang B, Shin S, Kensler TW (2007) Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radical Biol Med 43(5):809–817
Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008) Dual roles of Nrf2 in cancer. Pharmacol Res 58(5–6):262–270. https://doi.org/10.1016/j.phrs.2008.09.003
Lee CH, Chen LC, Yu CC, Lin WH, Lin VC, Huang CY et al (2019) Prognostic value of CD1B in localised prostate Cancer. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16234723
Leng Z, Xia Q, Chen J, Li Y, Xu J, Zhao E et al (2018) Lgr5+ CD44+ EpCAM+ strictly defines cancer stem cells in human colorectal cancer. Cell Physiol Biochem 46(2):860–872
Li X, Zhao H, Gu J, Zheng L (2015) Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. Int J Clin Exp Pathol 8(10):12084–12092
Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y (2017) Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep 7(1):13856. https://doi.org/10.1038/s41598-017-14364-2
Liou G-Y, Storz P (2010) Reactive oxygen species in cancer. Free Radical Res 44(5):479–496
Maghsoodi MS, Khosroshahi NS, Beilankouhi EAV, Valilo M, Feizi MAH (2023) VEGF-634G> C (rs2010963) gene polymorphism and high risk of breast cancer in the Northwest of Iran. Indian J Gynecol Oncol 21(1):6
Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, Klaassen CD (2008) Nrf2-and PPARα-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106(2):319–328
Mahmoudi S, Ghorbani M, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N (2019) Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells. J Drug Deliv Sci Technol 49:268–276
Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C et al (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38(17):5718–5734
Mao X, Chen Y, Lu X, Jin S, Jiang P, Deng Z et al (2023) Tissue resident memory T cells are enriched and dysfunctional in effusion of patients with malignant tumor. J Cancer 14(7):1223
Marcato P, Dean CA, Giacomantonio CA, Lee PW (2011) Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 10(9):1378–1384. https://doi.org/10.4161/cc.10.9.15486
Maroufi NF, Vahedian V, Hemati S, Rashidi M-R, Akbarzadeh M, Zahedi M et al (2020) Targeting cancer stem cells by melatonin: effective therapy for cancer treatment. Pathol-Res Pract 216(5):152919
Marquardt S, Solanki M, Spitschak A, Vera J, Puetzer BM (2018) Emerging functional markers for cancer stem cell-based therapies: understanding signaling networks for targeting metastasis. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2018.06.006
Masko EM, Alfaqih MA, Solomon KR, Barry WT, Newgard CB, Muehlbauer MJ et al (2017) Evidence for feedback regulation following cholesterol lowering therapy in a prostate cancer xenograft model. Prostate 77(5):446–457
Matsui WH (2016) Cancer stem cell signaling pathways. Medicine. https://doi.org/10.1097/MD.0000000000004765
McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI et al (2001) The Cap ‘n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61(8):3299–3307
Mei D, Lv B, Chen B, Xiao S, Jiang J, Xie Y, Jiang L (2017) All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis. PLoS ONE 12(8):e0182835
Ménard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22(42):6570–6578. https://doi.org/10.1038/sj.onc.1206779
Menegon S, Columbano A, Giordano S (2016) The dual roles of NRF2 in cancer. Trends Mol Med 22(7):578–593. https://doi.org/10.1016/j.molmed.2016.05.002
Miyata T, Yoshimatsu T, So T, Oyama T, Uramoto H, Osaki T et al (2015) Cancer stem cell markers in lung cancer. Pers Med Univ 4:40–45
Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H et al (2015) Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 137(2):299–305
Moreb JS, Ucar-Bilyeu DA, Khan A (2017) Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells. Cancer Chemother Pharmacol 79:295–301
Morgan MJ, Liu Z-G (2011) Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 21(1):103–115. https://doi.org/10.1038/cr.2010.178
Najafi M, Farhood B, Mortezaee K (2019) Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol 234(6):8381–8395. https://doi.org/10.1002/jcp.27740
Nguyen T, Nioi P, Pickett CB (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284(20):13291–13295
Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133. https://doi.org/10.1038/nrc3184
Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Fukusumi T et al (2015) Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26. Oncol Lett 9(5):2361–2367
Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K (2012) Expression of the potential cancer stem cell markers, CD 133, CD 44, ALDH 1, and β-catenin, in primary lung adenocarcinoma—their prognostic significance. Pathol Int 62(12):792–801
Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 47(19):6645–6653
Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358(13):1409–1411
Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A et al (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and MetastasisRANK induces EMT and stemness in the human breast. Cancer Res 72(11):2879–2888
Panieri E, Saso L (2019a) Potential applications of NRF2 inhibitors in cancer therapy. Oxid Med Cell Longev. https://doi.org/10.1155/2019/8592348
Panieri E, Saso L (2019b) Potential applications of NRF2 inhibitors in cancer therapy. Oxid Med Cell Longev. https://doi.org/10.1155/2019/8592348
Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13(3):1–9
Payandeh Z, Tazehkand AP, Barati G, Pouremamali F, Kahroba H, Baradaran B, Samadi N (2020) Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance. Biochimie 179:32–45
Poppleton H, Gilbertson R (2007) Stem cells of ependymoma. Br J Cancer 96(1):6–10
Pucci C, Martinelli C, Ciofani G (2019) Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. https://doi.org/10.3332/ecancer.2019.961
Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L (2021) HER2 signaling and breast cancer stem cells: the bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness. Cancers 13(19):4778
Püschel J, Dubrovska A, Gorodetska I (2021) The multifaceted role of aldehyde dehydrogenases in prostate cancer stem cells. Cancers 13(18):4703
Qin J-J, Cheng X-D, Zhang J, Zhang W-D (2019) Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. Cell Commun Signal 17(1):1–15
Raghunath A, Sundarraj K, Nagarajan R, Arfuso F, Bian J, Kumar AP et al (2018) Antioxidant response elements: discovery, classes, regulation and potential applications. Redox Biol 17:297–314. https://doi.org/10.1016/j.redox.2018.05.002
Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S, Arshad M (2017) ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol 143(9):1789–1809
Reddy NM, Kleeberger SR, Cho H-Y, Yamamoto M, Kensler TW, Biswal S, Reddy SP (2007) Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants. Am J Respir Cell Mol Biol 37(1):3–8
Ren F, Sheng WQ, Du X (2013) CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol 19(17):2603–2611. https://doi.org/10.3748/wjg.v19.i17.2603
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med 49(11):1603–1616. https://doi.org/10.1016/j.freeradbiomed.2010.09.006
Rezaeeyan H, Shahrabi S, McKee TD, Saki N (2018) The expression of CD markers in solid tumors: significance in metastasis and prognostic value.
Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12:S3–S8
Ryoo I-G, Lee S-H, Kwak M-K (2016) Redox modulating NRF2: a potential mediator of cancer stem cell resistance. Oxid Med Cell Longev. https://doi.org/10.1155/2016/2428153
Sagakyants A, Kit O, Ulyanova E, Zlatnik EY, Novikova I, Shulgina O et al (2021) Features of expression of CD133 and CD44 markers of tumor stem cells with metastatic and non-metastatic gastric cancer. Sib J Oncol 20(1):97–104
Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M et al (2006) CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 131(2):630–639
Sand A, Piacsek M, Donohoe DL, Duffin AT, Riddell GT, Sun C et al (2020) WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer. Cancer Lett 472:119–131
Sargazi Z, Yazdani Y, Tahavvori A, Youshanlouei HR, Alivirdiloo V, Beilankouhi EAV, Valilo M (2023) NFR2/ABC transporter axis in drug resistance of breast cancer cells. Mol Biol Rep. https://doi.org/10.1007/s11033-023-08384-7
Saygin C, Matei D, Majeti R, Reizes O, Lathia JD (2019) Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell 24(1):25–40
Shah D, Osipo C (2016) Cancer stem cells and HER2 positive breast cancer: the story so far. Genes Dis 3(2):114–123
Shi X, Zhang Y, Zheng J, Pan J (2012) Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 16(11):121C5-1228. https://doi.org/10.1089/ars.2012.4529
Son Y, Kim S, Chung H-T, Pae H-O (2013) Chapter Two—reactive oxygen species in the activation of MAP kinases. In: Cadenas E, Packer L (eds) Methods in enzymology, vol 528. Academic Press, Cambridge, pp 27–48
Soundararajan P, Kim JS (2018) Anti-carcinogenic glucosinolates in cruciferous vegetables and their antagonistic effects on prevention of cancers. Molecules. https://doi.org/10.3390/molecules23112983
Sui X, Cai J, Li H, He C, Zhou C, Dong Y et al (2018) p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer. Cell Death Dis 9(5):523
Sukowati CHC, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C (2013) The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS ONE 8(10):e76830–e76830. https://doi.org/10.1371/journal.pone.0076830
Sun T, Chen G, Li Y, Xie X, Zhou Y, Du Z (2015) Aggressive invasion is observed in CD133-/A2B5+ glioma-initiating cells. Oncol Lett 10(6):3399–3406
Taguchi K, Yamamoto M (2017) The KEAP1-NRF2 system in cancer. Front Oncol 7:85–85. https://doi.org/10.3389/fonc.2017.00085
Tahavvori A, Gargari MK, Yazdani Y, Mamalo AS, Beilankouhi EAV, Valilo M (2023) Involvement of antioxidant enzymes in Parkinson’s disease. Pathol-Res Pract 249:154757
Tan BT, Park CY, Ailles LE, Weissman IL (2006) The cancer stem cell hypothesis: a work in progress. Lab Invest 86(12):1203–1207
Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S (2019) Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol 234(3):2134–2142
Tian Z, Yang Y, Wu H, Chen Y, Jia H, Zhu L, et al. (2022) Synergistic effects of Nrf2 inhibitor, brusatol treatment in combination with lapatinib, a selective HER2 tyrosine kinase inhibitor in HER2-positive cancers.
Toledo-Guzmán ME, Hernandez MI, Gómez-Gallegos ÁA, Ortiz-Sánchez E (2019) ALDH as a stem cell marker in solid tumors. Curr Stem Cell Res Ther 14(5):375–388
Tomita H, Tanaka K, Tanaka T, Hara A (2016) Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 7(10):11018–11032. https://doi.org/10.18632/oncotarget.6920
Trempus CS, Morris RJ, Ehinger M, Elmore A, Bortner CD, Ito M et al (2007) CD34 expression by hair follicle stem cells is required for skin tumor development in mice. Cancer Res 67(9):4173–4181. https://doi.org/10.1158/0008-5472.CAN-06-3128
Tu W, Wang H, Li S, Liu Q, Sha H (2019) The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases. Aging Dis 10(3):637–651. https://doi.org/10.14336/AD.2018.0513
Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD (P) H: quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93(25):14960–14965
Victorino VJ, Campos FC, Herrera AC, Colado Simao AN, Cecchini AL, Panis C, Cecchini R (2014a) Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. Tumour Biol 35(4):3025–3034. https://doi.org/10.1007/s13277-013-1391-x
Victorino VJ, Campos FC, Herrera AC, Colado Simao AN, Cecchini AL, Panis C, Cecchini R (2014b) Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. Tumor Biol 35:3025–3034
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525–532
Wang J, Yi J (2008) Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 7(12):1875–1884. https://doi.org/10.4161/cbt.7.12.7067
Wang J, Zhang B, Wu H, Cai J, Sui X, Wang Y et al (2017) CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells. Oncogene 36(10):1351–1363
Wang Y-Y, Chen J, Liu X-M, Zhao R, Zhe H (2018) Nrf2-mediated metabolic reprogramming in cancer. Oxid Med Cell Longev. https://doi.org/10.1155/2018/9304091
Wasfy RE, El-Guindy DM (2017) CD133 and CD44 as cancer stem cell markers in bladder carcinoma: an immunohistochemical study. Egyptian J Pathol 37(1):204–208. https://doi.org/10.1097/01.xej.0000520912.41715.09
Wattanawongdon W, Bathpho TS, Tongtawee T (2021) Co-expression of LGR5 and CD133 cancer stem cell predicts a poor prognosis in patients with gastric cancer. Turk J Gastroenterol 32(3):261–268. https://doi.org/10.5152/tjg.2021.20108
Wen L, Cheng F, Zhou Y, Yin C (2015) MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol 21(5):313
Woo Y, Oh J, Kim JS (2017) Suppression of Nrf2 activity by chestnut leaf extract increases chemosensitivity of breast cancer stem cells to paclitaxel. Nutrients. https://doi.org/10.3390/nu9070760
Wu T, Harder BG, Wong PK, Lang JE, Zhang DD (2015) Oxidative stress, mammospheres and Nrf2–new implication for breast cancer therapy? Mol Carcinog 54(11):1494–1502
Xia L, Ma W, Afrashteh A, Sajadi MA, Fakheri H, Valilo M (2023) The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer. Biochemia Medica 33(3):266–278
Yamamoto M, Kensler TW, Motohashi H (2018) The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev 98(3):1169–1203
Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12(8):553–563
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137
Yu Z, Pestell TG, Lisanti MP, Pestell RG (2012) Cancer stem cells. Int J Biochem Cell Biol 44(12):2144–2151
Zavros Y (2017) Initiation and maintenance of gastric cancer: a focus on CD44 variant isoforms and cancer stem cells. Cell Mol Gastroenterol Hepatol 4(1):55–63. https://doi.org/10.1016/j.jcmgh.2017.03.003
Zeglinski M, Ludke A, Jassal DS, Singal PK (2011) Trastuzumab-induced cardiac dysfunction: a ‘dual-hit.’ Exp Clin Cardiol 16(3):70
Zhang Y, Yang JH (2013) Activation of the PI3K/Akt pathway by oxidative stress mediates high glucose-induced increase of adipogenic differentiation in primary rat osteoblasts. J Cell Biochem 114(11):2595–2602. https://doi.org/10.1002/jcb.24607
Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S et al (2021) Aldehyde dehydrogenase 2 mediates alcohol-induced colorectal cancer immune escape through stabilizing PD-L1 expression. Adv Sci 8(10):2003404
Zhu J, Wang H, Sun Q, Ji X, Zhu L, Cong Z et al (2013) Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer 13(1):1–11
Zhu Y, Huang R, Wu Z, Song S, Cheng L, Zhu R (2021) Deep learning-based predictive identification of neural stem cell differentiation. Nat Commun 12(1):2614
Acknowledgements
The authors would like to thank Urmia University of Medical Sciences for their support of this research.
Funding
The authors declare that the study had no funding.
Author information
Authors and Affiliations
Contributions
A. F., S. T., and S. P. were involved in data collection. M. S., M. Q., and M. H. were involved in writing the article and drawing the figures. A. N. was involved in revising. M. V. participated in the study design.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflict of interest with respect to research, authorship, and/or publication of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fakhrioliaei, A., Tanhaei, S., Pakmehr, S. et al. Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review. J Membrane Biol 257, 3–16 (2024). https://doi.org/10.1007/s00232-024-00307-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00232-024-00307-2